ZRSR2
ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 2 more.
Overview
Pre-mRNA-binding protein required for splicing of both U2- and U12-type introns. Selectively interacts with the 3'-splice site of U2- and U12-type pre-mRNAs and promotes different steps in U2 and U12 intron splicing. Recruited to U12 pre-mRNAs in an ATP-dependent manner and is required for assembly of the pre-spliceosome, a precursor to other spliceosomal complexes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.42, genetic association 0.00, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 2 more.
- 1 · What it is
ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 2 more.
- 2 · What goes wrong in cancer
Pre-mRNA-binding protein required for splicing of both U2- and U12-type introns. Selectively interacts with the 3'-splice site of U2- and U12-type pre-mRNAs and promotes different steps in U2 and U12 intron splicing.
- 3 · How drugs use it
No product in this corpus aims at ZRSR2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:23019 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15696 (protein name, function text, keywords and locations (REST API)); CIViC gene ZRSR2 (1 evidence items, 0 assertions, 1 variants; diseases: Acute Myeloid Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000169249 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.51, skin cancer 0.52, myeloproliferative neoplasm 0.59, leukaemia 0.57 (GraphQL API, CC0)); IntOGen ZRSR2 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Pre-mRNA-binding protein required for splicing of both U2- and U12-type introns. Selectively interacts with the 3'-splice site of U2- and U12-type pre-mRNAs and promotes different steps in U2 and U12 intron splicing. Recruited to U12 pre-mRNAs in an ATP-dependent manner and is required for assembly of the pre-spliceosome, a precursor to other spliceosomal complexes. For U2-type introns, it is selectively and specifically required for the second step of splicing. Location: Nucleus (UniProt). Locus Xp22.2 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.59 with myeloproliferative neoplasm (MONDO_0020076)
- Leukaemia: Open Targets association 0.57 with leukaemia (MONDO_0005059)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908)
- Acute myeloid leukaemia: CIViC evidence names this disease; IntOGen driver in 1 cohort (AML)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZRSR2" OR ABSTRACT:"ZRSR2" OR TITLE:"zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2" OR ABSTRACT:"zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2" OR TITLE:"U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2" OR ABSTRACT:"U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2" OR TITLE:"U2AF1-RS2" OR ABSTRACT:"U2AF1-RS2" OR TITLE:"ZC3H22" OR ABSTRACT:"ZC3H22" OR TITLE:"U2AF1L2" OR ABSTRACT:"U2AF1L2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZRSR2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetGATA1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetSRSF2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetPRKCD
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute myeloid leukaemia.
- TargetCEBPA
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
- TargetJAK3
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetGATA2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetFANCE
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Acute myeloid leukaemia.
- TargetERCC4
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.